On January 23, 2026, Chairman and CEO Ford Robert B purchased 18,800 shares of ABT, bringing his total ownership to 216,203 shares. This represents a substantial personal investment and underscores management’s conviction in the company’s long-term strategy. Insider buying at the executive level is a positive indicator for investors, suggesting that leadership expects the recent challenges—particularly in the Nutrition segment—to be transitory and that future operating results will improve.

ABT’s Medical Devices segment continues to exhibit robust double-digit growth, led by its Continuous Glucose Monitoring products and vascular intervention platforms. That strength offset softer demand in Nutrition, where higher manufacturing costs and pricing pressures weighed on volumes. Management forecasts a mid-single-digit increase in overall revenues for the year ahead, driven by accelerating procedure volumes in cardiology and neurology and a return to growth in Nutrition during the second half of the fiscal year.

As a member of the Dividend Kings, ABT has increased its payout for 54 consecutive years, maintaining a yield in line with its peers in the healthcare sector. Looking forward, the pending acquisition of Exact Sciences is expected to close in Q2 2026 and will add an early-cancer-detection platform to ABT’s diagnostics portfolio. This move is projected to create a new growth vertical, diversify revenue streams further and enhance long-term shareholder value.